Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India—A Model-Based Economic Analysis

Patients with advanced and metastatic cervical cancer have a poor prognosis with a 1-year survival rate of 10%-15%. Recently, an antiangiogenic humanized monoclonal antibody bevacizumab has shown to improve the survival of these patients. This study was designed to assess the cost effectiveness of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Nidhi, Nehra, Prerika, Chauhan, Akashdeep Singh, Mehra, Nikita, Singh, Ashish, Krishnamurthy, Manjunath Nookala, Rajsekhar, Kavitha, Kalaiyarasi, Jayachandran Perumal, Roy, Partha Sarathi, Malik, Prabhat Singh, Mathew, Anisha, Malhotra, Pankaj, Kataki, Amal Chandra, Dixit, Jyoti, Gupta, Sudeep, Kumar, Lalit, Prinja, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932481/
https://www.ncbi.nlm.nih.gov/pubmed/35286136
http://dx.doi.org/10.1200/GO.21.00355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932481/
https://www.ncbi.nlm.nih.gov/pubmed/35286136
http://dx.doi.org/10.1200/GO.21.00355

Ejemplares similares